April 2016, Vol. 5, No. 3
Improving Value by Understanding Total Cost of Cancer Care
Aggressive cancer treatments, emergency department (ED) visits, and hospital admissions at the end of life are major cost drivers. The use of cost data to inform infrastructure investments can help cancer centers to move toward value-based payment models, improve end-of-life planning, and reduce futile care, according to Kerin Adelson, MD.
The more procedures performed, drugs prescribed, and hospitalizations made, “the more money feeds into your institution,” said Adelson, Assistant Professor of Medicine (Medical Oncology) and Chief Quality Officer and Deputy Chief Medical Officer for Smilow Cancer Hospital (SCH) at Yale-New Haven. “It’s aspirational to think the best, highest quality care would be remunerated accordingly, but for most institutions, this change still seems far off.”
“In healthcare, higher cost does not mean higher quality,” she continued. “Often in the setting of advanced disease, costly drugs, invasive procedures, and repeated hospitalizations do not improve outcomes.”
According to Adelson, cancer centers across the country are largely unprepared to move toward value-based payment, but her institution is tackling this challenge by analyzing cost data. She presented her group’s findings at the 2016 ASCO Quality Care Symposium.
Preparing for Value
“Step 1 of preparing for value is demonstrating that this is an opportunity, not a liability,” she stated. The inspiration for the value-based strategy at SCH was the Oncology Care Model (OCM) from the Centers for Medicare & Medicaid Services.
“OCM is a win-win,” she said. “We learn how to improve value without giving up fee-for-service, and we receive financial support to invest in infrastructure that will improve care.”
Medicare patients are enrolled at the time chemotherapy is initiated, in 6-month episodes, and fee-for-service is collected for all care delivery. The practice collects an additional $160 per patient per month to support new infrastructure and care processes. Performance-based payments are structured on the shared savings model, and quality metrics are met.
The 8 metrics associated with performance-based payments include such items as number of ED visits per patient/episode and number of hospital admissions per patient/episode, which she deemed “truly meaningful quality metrics…that could catalyze clinical transformation.”
The second step in preparing for value is knowing your strengths and building upon them, but also understanding your weaknesses.
The third step is understanding your population’s total cost of care. “This requires payer level data and cannot be obtained with your own institution’s financial reports. Understanding when in the trajectory of illness spending occurs and what care patterns lead to higher cost will identify opportunities for savings,” she said.
The researchers accessed the 5% Medicare Limited Data Set (2012-2013) to map out the cost of care in 6-month episodes for all Medicare patients receiving chemotherapy at SCH. “Indeed, we saw that 20% of cost is incurred outside of our health system,” said Adelson.
On average, a first episode of care at SCH cost $26,500, a second episode $38,000, and a third $45,600. Their analysis also demonstrated important associations between increases in spending and ED utilization. Patients who had 1 or fewer ED visits during an episode averaged $21,000 versus $49,000 for those with 2 or more. “This cost is driven by the downstream inpatient services,” she said. And patients who died during an episode cost $53,000 compared with $25,600 for patients who lived.
The Importance of Urgent Care
The investigators used their analysis to target infrastructure investments in urgent care, care management, and palliative care.
“The Medicare database showed us that our elderly population has substantial comorbidity, suggesting the need for better care management,” said Adelson. “We looked at causes of admissions outside the primary cancer diagnosis. Many of these could be prevented with enhanced ambulatory urgent care and extended early morning and evening hours.”
“Referrals to ambulatory palliative care earlier in the course of the disease will help patients express their wishes and goals, and for patients with disease progression, our goal is to initiate referrals to hospice from the ambulatory setting,” Adelson added. “This is a big change from our care today.”
The final step in preparing for value is planning for infrastructure investments that will align quality improvement and cost savings. “Changing how we care for patients at the end of life requires a major cultural shift, which is challenging for oncologists,” she said. “We will provide communication training for all of our oncologists and hematologists to help them elicit patient preferences earlier in the course of disease, and finally, we will implement clinical pathways to standardized evidence-based cost-effective care across our large network.”
“We believe these investments will lead to significant cost reductions,” she said.
Rather than establishing a clear winner, a debate (“Intralesional Monotherapy: Is There a Role?”) at the HemOnc Today Melanoma and Cutaneous Malignancies conference confirmed the words of Sanjiv S. Agarwala, MD, the meeting’s chairman and moderator: “Intralesional therapy is here to stay.” Roles for intralesional therapy as either monotherapy or [ Read More ]
A new biomarker can identify the subgroup of Class 1 uveal melanomas most likely to metastasize, according to a retrospective study published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR). Among Class 1 uveal melanomas, those with high levels of PRAME mRNA were more [ Read More ]